Perspectives for the Clinical Use of Aromatase Inhibitors

The enzyme aromatase catalyzes the rate-limiting step in estrogen biosynthesis in both men and women. The availability of more potent, selective and non-toxic aromatase inhibitors could potentially provide effective therapy for a number of estrogen-dependent diseases. Clinical application of these agents depends upon the physiologic source of estrogen and the ability of regulatory systems to counteract the effects of these inhibitors. Consequently, estrogen blockade might be more effective in postmenopausal women than in premenopausal women or in men. In assessing aromatase inhibitors, the various advantages and disadvantages of all the available strategies to block estrogen synthesis or action must be considered. Such analysis suggests that aromatase inhibitors will find an important place in the management of breast and endometrial carcinomas and possibly benign diseases such as endometriosis, leiomyomata uteri, perimenopausal bleeding and gynecomastia. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others

Siiteri, P.K. and MacDonald, P.C. In: Handbook of Physiology, Section 7: Endocrinology (Eds. E.O. Greep and E.B. Astwood), American Physiological Society, vol. II, part 1, Baltimore, 1973, pp. 615–629. Brodie, A.M.H. In: Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action (Eds. B.J.A. Furr and A.E. Wakeling), W.B. Saunders, England, pp. 255–270, 1987. Manni, A. and Santen, R.J. In: Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action (Eds. B.J.A. Furr and A.E. Wakeling), W.B. Saunders, England, pp. 271–287, 1987. Henderson, I.C. and Canellos, G.P. N. Eng. J. Med. 302:17–30, 78–90, 1980. Rose, C. and Mouridsen H. In : Abstracts of the International Symposium on Endocrine-Dependent Breast Cancer: Critical Assessment of Recent Advances, Budapest, August 23, 1986, abstract. Jackson, I.M. and Lowery, C. In : Pharmacology and Clinical Uses of Inhibitors of Hormone Secretion and Action (Eds. B.J.A. Furr and A.E. Wakeling), W.B. Saunders, England, pp. 87–105, 1987. Santen, R.J., English, H., Rohner, T., Drago, J., Lipton, A., Harvey, H., Simmonds, M., Boucher, A., Glode, L.M., Wettlaufer, J., Gordon, R. and Manni, A. In : EORTC Genitourinary Group Monograph 2, Part A: Therapeutic Principles in Metastatic Prostatic Cancer (Eds. F.H. Schroeder and B. Richards), Alan R: Liss, Inc., New York, pp. 359–371, 1985. Shaw, R.W., Fraser, H.M. and Boyle, H. Brit. Med. J. 287:1667–1669, 1983. Meldrum, D.R., Chang, R.J., Lu, J., Vale, W., Rivier, J. and Judd, H.L. J. Clin. Endocrinol. Metab. 54:1081–1083, 1982. Lemay, A., Maheux, R., Faure, N., Jean, C. and Fazekas, A.T.A. Fertil. Steril. 41:863–871, 1984. Maheux, R. and Lemay, A. Prog. Clin. Biol. Res. 225:297–311, 1986. Healy, D.L., Fraser, H.M. and Lawson, S.L. Brit. Med. J. 289:1267–1268, 1984. Pinotti, J.A., Tolosa, H.A. and Swini, F. J. Brasiliar. Gynecol. 87:57–59, 1979. Perez-Lopez, F.R., Lapresa, J.R. and Abdos, M.D. Endocrinologica 30:5–8, 1983. Riccardi, I. and Ianniruberto, A. Obstet. Gynecol. 54:80–84, 1979. Prevot, G., Lhuillier, P. and Leduc, B. Senologia 5:129–130, 1980. Shaaban, M.M., Morad, F. and Hassan, A.E.R.R. Int. J. Gynecol. Obstet. 18:348–350, 1980. Fentiman, J.S., Caleffi, M., Brami, K., Chaudhury, M.A. and Haywood, J.L. The Lancet 11:287–288, 1986. Stepanas, A.V., Burnet, R.B., Harding, P.E. and Wise, P.H. J. Pediatr. 90:651–653, 1977. Plourde, P.V., Kulin, H.E. and Santner, S.J. Amer. J. Dis. Child. 137:1080–1082, 1983. LeRoith, D., Sobel, R. and Glick, S.M. Acta Endocrinol. 95:177–180, 1980. Zachmann, M., Eiholzer, U., Muritano, M., Werder, E.A. and Manella, B. Acta Endocrinol. Supp. 279:218–226, 1986. Schill, W.-B. Andrologia 11:77–107, 1979. Vermeulen, A. and Comhaire, F. Fertil. Steril. 29:320–327, 1978. Buvat, J., Ardaens, K., Lemaire, A., Gauthier, A., Gasnault, J.P. and Buvat-Herbaut, M. Fertil. Steril. 39:700–703, 1983. Schill, W.-B. and Landthaler, M. Andrologia 12:546–548, 1980. Traub, A.I. and Thompson, W. Andrologia 13:486–490, 1981. Vigersky, R.A. and Glass, A.R. J. Clin. Endocrinol. Metab. 52:897–902, 1981. Feuillan, P.P., Foster, CM., Pescovitz, O.H., Hench, K.D., Shawker, T., Dwyer, A., Malley, J.D., Barnes, K., Loriaux, D.L. and Cutler, Jr., G.B. New Engl. J. Med. 315:1115–1119, 1986. Laue, L., Keningsberg, D., Pescovitz, O., Barnes, K., Hench, K., Loriaux, D.L. and Cutler, G.B. In: Program and Abstracts: Aromatase: Future Perspectives, Miami, Florida, March 4–7, 1987, abstract. Santen, R.J., Worgul, T.J., Lipton, A., Harvey, H., Boucher, A., Samojlik, E. and Wells, S.A. Ann. Int. Med. 96:94–101, 1982. Santen, R.J., Leszczynski, D., Tilson-Mallet, N., Feil, P.D., Wright, C, Manni, A. and Santner, S.J. In: Endocrinology of the Breast: Basic and Clinical Aspects (Eds. A. Angeli, H.L. Bradlow and L. Dogliotti), New York Academy of Sciences, Publishers, New York, 1986, pp. 126–137. Santen, R.J. Breast Cancer Res. Treat. 7:23–36, 1986. Taylor, I.W., Hodson, P.J., Green, M.D., Sutherland, R.L. Cancer Res. 43:4007–4010, 1983. Santen, R.J., Samojlik, E. and Wells, S.A. J. Clin. Endocrinol. Metab. 51:473–477, 1980. Author information Authors and Affiliations Editor information Editors and Affiliations Rights and permissions Copyright information © 1988 Kluwer Academic Publishers, Boston About this chapter Cite this chapter Santen, R.J. (1988). Perspectives for the Clinical Use of Aromatase Inhibitors. In: Rich, M.A., Hager, J.C., Lopez, D.M. (eds) Breast Cancer: Scientific and Clinical Progress. Developments in Oncology, vol 56. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1753-1_19 Download citation DOI: https://doi.org/10.1007/978-1-4613-1753-1_19 Publisher Name: Springer, Boston, MA Print ISBN: 978-1-4612-8984-5 Online ISBN: 978-1-4613-1753-1 eBook Packages: Springer Book Archive

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.